For Health Care Professionals Outside the United States

Consequences of VOCs

VOCs are the clinical hallmark of SCD.2 Learn why preventing VOCs is important for your patients.

Learn more

VOC Prevention

ADAKVEO was proven to prevent VOCs across all patient types in the SUSTAIN clinical trial.1

See the efficacy results

The History of ADAKVEO

Learn about the scientific discoveries that led to the development of ADAKVEO.

Watch the video

ADAKVEO Mechanism of Action

ADAKVEO is the first and only approved targeted monoclonal antibody that works by inhibiting P-selectin-mediated multicellular adhesion in SCD—thereby preventing vaso-occlusion.1,3

See how the pathogenesis of VOCs involves more than sickled red blood cells


ADAKVEO® (crizanlizumab) IV infusion is indicated for the prevention of vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and over.

SCD, sickle cell disease; VOCs, vaso-occlusive crises.
References: 1. Adakveo [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2021. 2. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647-3656. 3. National Heart, Lung, and Blood Institute. SBIR Success Stories. NHLBI funding leads to promising drug candidate to prevent sickle cell pain. Accessed November 8, 2021.